Global /China /Healthcare /Drug Manufacturers - Specialty & Generic /300039
chevron_leftBack
Shanghai Kaibao Pharmaceutical CO.,Ltd logo

Shanghai Kaibao Pharmaceutical CO.,Ltd

300039
SHE: 300039 Delayed
5.78CNY -0.7%
0.8542 USD
As of 9 June 2026, Shanghai Kaibao Pharmaceutical CO.,Ltd has a market cap of $899.65M USD, ranking #11319 globally and #3267 in China. It ranks #1020 in the Healthcare sector, and #56 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
11319
Country Rank
3267
Sector Rank
1020
Industry Rank
56
Key Stats
Market Cap
$899.65MUSD
6.09B CNY
Enterprise Value
$739.12MUSD
5.0B CNY
Revenue (TTM)
$152.99MUSD
1.04B CNY
EBITDA (TTM)
$41.48MUSD
280.7M CNY
Net Income (TTM)
$38.3MUSD
259.16M CNY
EBITDA Margin
27%
Profit Margin
25%
PE Ratio
23.5
PS Ratio
5.9
PB Ratio
1.3
EV/EBITDA
17.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yingbin Zhou open_in_new
Employees
1,225
Founded
2000
Website
xykb.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.7% -0.3% -2.4% -7.8% -6.3% -2%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300039
上海凯宝药业股份有限公司 Class A
ISIN: CNE100000JZ3
Shares Out.:
916.558M1 Shares Float: 916.398M2
TV:
SA:
YF:
GF:
BA:
MS:
5.78 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Kaibao Pharmaceutical CO.,Ltd

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai’an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. The company was founded in 2000 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (China)
Name
Market Cap diff.
PE
$15.86B
107.34B CNY
2K%
16.0
$9.1B
61.6B CNY
912%
80.6
$5.22B
35.33B CNY
480%
20.0
$4.21B
28.47B CNY
368%
20.8
$3.27B
22.12B CNY
263%
8.1
$2.74B
18.55B CNY
205%
11.5
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$37.19B
108.92B ILS
4K%
24.2
$29.56B
3K%
-
CIPLA
$11.13B
1.06T INR
1K%
23.4
LUPIN
$11.02B
1.05T INR
1K%
22.7
$8.72B
7.57B EUR
870%
-
AUROPHARMA
$8.44B
807.02B INR
838%
23.1
chevron_leftBack